CNS Pharmaceuticals, Inc. has entered into an agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which is being tested on a range of viruses including the coronavirus SARS-CoV-2. WPD previously licensed rights to a portfolio of drug candidates, including WP1122, from Moleculin Biotech, Inc. for certain territories. WP1122 is a prodrug of 2-DG (2-deoxy-D-glucose) that, based on recent preclinical data, appears to overcome 2-DG&#...